Europe Has Thousands of Aging Researchers — They’re Barely Talking to Each Other
Aging research in Europe is well-funded and growing fast. But scientists in different countries are largely working in isolation, duplicating efforts and missing insights that only emerge from sharing data at scale…
A commentary published in Nature Aging by the founders of the European Federation for Aging Research (EFAR) makes a case that is uncomfortable in its simplicity: despite a surge in publications and funding, aging research across Europe remains fragmented. Labs in Copenhagen, Barcelona, and Berlin are tackling overlapping questions without sharing data, methods, or biobanks. The result is slower discovery and wasted resources.
EFAR aims to change that by connecting national research networks, building shared infrastructure, and developing a common language for what ‘healthy aging’ actually means — a concept that is applied with surprising inconsistency across the scientific literature. The organisation explicitly targets the gap between basic science and clinical application: many findings from cell biology and animal studies never reach patients.
Nine rooms, no corridor
The European aging research landscape has a paradoxical quality. Strong research centers exist. Political will is present — the EU has made aging a priority within Horizon Europe. A growing private sector is investing in longevity technologies. But the scientific infrastructure resembles nine rooms with no connecting corridor. Clinical trials are duplicated. Cohorts are not harmonized. Measures of biological age vary so much across studies that direct comparison is almost meaningless.
The authors argue for standardization of aging biomarkers — measurable indicators of biological aging such as DNA methylation patterns, telomere length, and inflammatory markers. The practical implication is significant: if researchers in Amsterdam and Warsaw use the same measures, they can pool data and analyze far larger populations. That increases the chance of detecting subtle associations that remain invisible in small cohorts.
Coordination or bureaucracy?
Critics of umbrella initiatives like this point to a risk the authors do not address directly: coordination structures can become bureaucratic and consume more energy than they produce. European scientific history has examples of ambitious networks that stalled on funding arrangements and governance complexity.
Whether EFAR avoids that fate depends on what it delivers concretely in the next few years. The agenda is clear. The execution is the real test.